Title
Category
Credits
Event date
Cost
Unlocking the Alzheimer’s Brain: How Radiological Tools and Biomarkers Hold the Key to Early Diagnosis and Decision-Making
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
$0.00
Program DescriptionThe age of disease-modifying therapy in Alzheimer’s disease (AD) is now a reality with two amyloid beta targeting therapies (ATT) now approved. Both agents require early diagnosis and therapeutic initiation to exert their effects. Not only is imaging a key component for the diagnosis of AD and to determine ATT eligibility, but all ATTs have the potential for unique adverse effects called amyloid-related imaging abnormalities (ARIA), necessitating frequent MRI monitoring and evaluation.
Over-Impacted, Under-Represented: Addressing Health Disparities in Multiple Sclerosis
$0.00
Program DescriptionThe prevalence of multiple sclerosis (MS) in racial and ethnic minority groups appears to be growing and its prognosis among these groups is often worse. With its historical management strategies formulated almost exclusively around patients of Caucasian descent, MS has a pressing need for improved approaches in patients of minority backgrounds. However, minimal guidance is publicly available on how to best meet the needs of diverse patient populations.
Decoding CIDP Strategies to Overcome Common Diagnostic and Therapeutic Pitfalls
$0.00
Due to the unique educational design of this course, the content must be viewed and completed on the myCME platform.Program DescriptionChronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder whose treatment landscape has recently expanded with the introduction of novel therapies with unique mechanisms of action and routes of administration. Despite these advances, CIDP is prone to misdiagnosis.

Pages